环孢霉素A逆转人白血病耐药细胞系HL-60/ADM及其超微弱发光的观察

目的:探讨环孢霉素A(CSA)对抗阿霉素人急性早幼粒白血病细胞系HL-60/ADM的耐药逆转作用,并比较二者之超微弱发光强度的特点。方法:选择环孢霉素A(CSA)作为耐药逆转剂,分别采用MTT法、流式细胞仪和免疫组化法分析CSA对人白血病耐药细胞系的毒性及逆转效果;用IFFM-D型流动式化学发光仪检测细胞的超微弱发光强度。结果:当CSA浓度在4ug/mL以下时,对HL-60/ADM无明显毒性作用,超过此浓度,其毒性呈剂量效应(P＜0．001)。当CSA浓度为0．5ug/mL时就有明显逆转作用,随着CSA剂量增加,逆转作用逐渐增强(P＜0．01),当CSA剂量达8ug/mL以上时对细胞存活产生明显的影响;流式细胞仪分析细胞周期可见逆转耐药细胞系HL-60/ADM CSA较耐药细胞系HL-60/ADM的G2期细胞显著增多,而S期细胞明显减少(P＜0．01);免疫组化结果显示HL-60/ADM细胞膜上P-gp高表达,经CSA作用后其表达下降;在10-4mol/L鲁米诺及0．3%双氧水条件下HL-60/ADM细胞超微弱发光强度高于用CSA逆转后的细胞(P＜0．001)。结论:CSA能有效逆转HL-60/ADM的耐药性;逆转后细胞超微弱发光强度值的降低可能与其细胞增殖速度减慢,DNA复制减少,细胞内氧化代谢减弱以及自由基水平降低等因素有关。     

姜黄素通过下调P-糖蛋白和热休克蛋白70逆转耐热肝癌细胞的阿霉素耐受性

探讨姜黄素对耐热肝癌细胞 (HepG2/TT) 阿霉素耐受性的逆转作用及其机制．用MTT检测细胞活力,PI染色流式细胞术检测细胞凋亡,高效液相色谱法检测细胞内阿霉素的积累,Western blot检测细胞P-糖蛋白 (P-glycoprotein,P-gp)、热休克蛋白70 (heat shock protein 70, Hsp70) 和caspase-3 的表达．耐热肝癌细胞HepG2/TT能耐受阿霉素引起的细胞毒性和 凋亡;姜黄素在5、10和20 μmol/L时,能浓度依赖性地降低阿霉素对HepG2/TT 细胞的IC50,增强阿霉素对HepG2/TT 细胞的凋亡诱导作用．耐热肝癌细胞HepG2/TT 与非耐热肝癌细胞HepG2比较,其P-gp和Hsp70 的表达水平明显增高; 10 μmol/L姜黄素处理24 h 后,HepG2/TT细胞P-gp和Hsp70的表达水平显著下降．HepG2/TT 细胞内阿霉素的积累低于HepG2细胞;10 μmol/L姜黄素处理 3 h后,HepG2/TT 细胞内阿霉素的积累明显增加．HepG2/TT细胞能抑制阿霉素激活 caspase-3;10 μmol/L姜黄素处理24 h后,阿霉素对 HepG2/TT细胞caspase-3的激活作用增强．上述结果表明,姜黄素能逆转耐热肝癌细胞HepG2/TT的阿霉素耐受性,其机制可能与其下调P-gp和Hsp70的表达,进而促进阿霉素激活caspase-3 有关．     

川芎嗪逆转人乳腺癌MCF-7/ADM细胞对阿霉素的耐药性

目的 探讨川芎嗪（tetramethylpyrazine,TMP）逆转人乳腺癌MCF-7/ADM细胞对阿霉素（ADM）的耐药性.方法 MTT法测定细胞的药敏性,荧光分光光度法检测细胞内阿霉素浓度的变化,流式细胞术检测耐药细胞凋亡百分率的变化.结果 非细胞毒性剂量（320 mg/L）及低毒剂量（1250 mg/L）川芎嗪均能显著降低MCF-7/ADM的IC50（P＜0.01）,逆转倍数分别为2.13倍和2.82倍;均能显著增加耐药细胞内ADM的浓度（P＜0.01）.320 mg/L川芎嗪能显著增加耐药细胞的凋亡百分率（P＜0.01）.结论 川芎嗪具有部分逆转人乳腺癌MCF-7/ADM细胞对阿霉素的耐药性,其逆转机制与增加细胞内ADM浓度有关.     

大蒜素诱导人白血病HL-60细胞程序性坏死及分子机制的研究

目的:研究大蒜素对人白血病HL-60细胞的抗肿瘤作用,检测程序性坏死明确大蒜素处理后HL-60细胞的死亡方式,并以JNK、RIP1和RIP3为靶点探讨可能的分子机制。方法:不同浓度大蒜素处理HL-60细胞后,在不同时间点采用MTT法检测细胞活力,使用非选择性caspase抑制剂z-vad-fmk研究细胞凋亡在其中的作用;50μM大蒜素处理HL-60细胞后,检测LDH释放量和PI染色阳性细胞比例反映细胞程序性坏死程度,采用免疫印迹法检测各时间点RIP1、RIP3表达和JNK磷酸化程度;使用JNK特异性抑制剂SP600125处理HL-60细胞,采用免疫共沉淀法检测RIP1与RIP3相互作用,并通过检测细胞活力、LDH释放量和PI染色阳性细胞比例研究JNK在大蒜素抗白血病活性中的作用。结果:大蒜素可显著抑制人白血病HL-60细胞增殖,这种作用并不完全依赖于诱导细胞凋亡;50μM大蒜素可诱导HL-60细胞发生程序性坏死,这种作用可被程序性坏死的特异性抑制剂necrostatin-1逆转;50μM大蒜素可显著增加HL-60细胞RIP1的表达和JNK的磷酸化水平,而对RIP3的表达无明显影响;50μM大蒜素可显著增加RIP1与RIP3的相互作用,使用JNK特异性抑制剂SP600125可逆转大蒜素的抗白血病作用。结论:一定剂量的大蒜素可通过激活JNK增加RIP1与RIP3的相互作用,诱导人白血病HL-60细胞发生程序性坏死,进而发挥抗白血病作用。     

三氧化二砷通过激活Drp-1增加人白血病HL-60细胞的放疗敏感性

目的:研究三氧化二砷(Arsenic trioxide,ATO)对人白血病HL-60细胞放疗敏感性的影响,并以动力相关蛋白-1(dynamin-related protein 1,Drp-1)为靶点探讨其可能的机制。方法:1μg/m L浓度的ATO处理HL-60细胞后使用20Gy强度进行放疗,采用MTT法检测细胞活力,流式细胞术检测细胞凋亡,通过线粒体钙离子缓冲能力检测线粒体钙离子代谢障碍,采用免疫印迹法检测Drp-1蛋白表达,并通过Drp-1阻滞剂mdivi-1预处理的方法检测Drp-1在实验中的作用。结果:1μg/m L浓度的ATO对HL-60细胞活力无影响,但可显著增加20Gy放疗所致的细胞活力下降、细胞凋亡和线粒体钙离子代谢障碍;1μg/m L浓度的ATO可显著增加Drp-1蛋白表达,使用mdivi-1预处理可部分逆转ATO的放疗增敏作用。结论:一定剂量的ATO可增加人白血病HL-60细胞的放疗敏感性,而这一作用可能是通过激活Drp-1蛋白表达而实现。     

阿霉素-姜黄素聚氰基丙烯酸正丁酯复方纳米粒的研制及逆转MCF-7/ADR细胞多药耐药的研究

采用乳化聚合法制备阿霉素-姜黄素聚氰基丙烯酸正丁酯复方纳米粒(DOX-CUR-PBCA-NPs),该纳米粒平均粒径为133±5.34nm,Zeta电位为+32.23±4.56 mV,阿霉素(DOX)和姜黄素(CUR)的包封率分别为49.98±3.32％,94.52±3.14％.MTT实验结果和Western blott实验结果均表明,DOX-CUR-PBCA-NPs与CUR-PBCA-NPs+DOX-PBCA-NPs体外对MCF-7/ADR细胞的生长抑制活性相当,下调MCF-7/ADR细胞中P-糖蛋白(P-gp)的表达也相当,较没有用PBCA纳米粒包载的游离药物、单一药物的纳米制剂及其他形式的制剂联用的抗肿瘤活性及逆转多药耐药的性能都显著增强.说明利用PBCA纳米粒同时包裹抗癌药物阿霉素与中药逆转剂姜黄素协同用药可以增强克服多药耐药(MDR)的疗效.     

三氧化二砷通过线粒体途径诱导人白血病HL-60细胞凋亡

目的:研究三氧化二砷(Arsenic trioxide,ATO)对人白血病HL-60细胞凋亡的影响,并以线粒体通路为靶点探讨其可能的机制。方法:采用1μg/m L、5μg/m L及10μg/m LATO处理HL-60细胞24小时后,采用流式细胞术检测细胞凋亡情况,通过细胞内MDA与GSH含量检测反映氧化应激水平,采用免疫印迹法检测凋亡相关分子表达,并通过免疫荧光染色检测细胞线粒体膜电位(mitochondrial membrane potential,MMP)水平。结果:5μg/m L及10μg/m L ATO可显著诱导人白血病HL-60细胞凋亡,并显著增加其氧化应激水平,增加促凋亡分子Bax和Caspase-3的表达,而抑制抗凋亡分子Bcl-2的表达,降低HL-60细胞线粒体膜电位的水平。结论:一定剂量的ATO可诱导人白血病HL-60细胞凋亡,而这一作用可能是通过诱导线粒体相关性凋亡信号通路激活实现。     

DADS诱导HL-60 G2/M期阻滞消减文库的构建与初步筛选

目的:构建DADS诱导HL60-细胞G2/M期阻滞的差异表达文库,初步筛选相关基因.方法:分别提取无DADS和有DADS处理HL-60细胞的总RNA和mRNA,构建消减cDNA文库.随即挑选正向SSH的阳性克隆,PCR检测插入片段,将含插入片段的克隆测序.Blastn分析差异cDNA片段的同源性.结果:构建了DADS诱导人白血病HL-60细胞G2/M期阻滞差异表达文库,其中包含120个正向SSH的克隆和100个反向SSH的克隆.50个随机正向SSH的克隆测序、比较同源性,发现5个新EST片段,已经在GenBank中登录.结论:所构建的DADS诱导人白血病HL-60细胞G2/M期阻滞消减文库为进一步筛选白血病HL-60细胞G2/M期阻滞相关基因奠定了基础.     

茯苓素对人白血病细胞系HL—60的诱导分化作用

本文报道了茯苓素对人急性早幼粒白血病细胞系HL-60的诱导分化作用。用12.5-100μg/ml茯苓素处理4天,50—80％以上的HL-60细胞获得还原NBT染料的能力。细胞形态及细胞化学反应发生显著变化。溶酶体酶含量显著增加,并获得吞噬乳胶颗粒的能力,分化为单核巨噬样细胞。茯苓素诱导HL-60细胞分化需持续作用48小时以上,诱导分化作用为不可逆性。     

全反维甲酸协同增强阿霉素对去势抵抗前列腺癌的疗效

[目的]探究全反维甲酸与阿霉素联用对去势抵抗前列腺癌的疗效。[方法]以PC3细胞作为去势抵抗前列腺癌细胞模型,MTT法检测联合用药对细胞的增殖抑制效果;流式细胞仪检测联合用药对细胞凋亡和细胞周期的影响;反转录PCR检测联合用药对凋亡相关基因表达的影响。[结果]2μmol/L全反维甲酸与80 nmol/L阿霉素联用协同增强对PC3细胞的抑制效果(为51.2±1.41%),与单独用药存在显著性差异(P0.05),促进PC3细胞的凋亡(为17.80±0.54%),同时阻滞细胞的G1和G2期,上调Bax及caspase 3基因的表达,下调Bcl-2基因的表达。[结论]全反维甲酸与阿霉素联用可增强对PC3细胞的增殖抑制和凋亡效果,Bcl-2、Bax及caspase 3基因参与了联合用药诱导PC3细胞凋亡的调控,从而增强对PC3细胞的疗效。     

Linoleic acid-grafted chitosan oligosaccharide micelles for intracellular drug delivery and reverse drug resistance of tumor cells

Intracellular drug delivery is an important rout to reverse drug resistance of tumor cells. In this study, the linoleic acid (LA)-grafted chitosan oligosaccharide (CSO) was synthesized to construct a micellar delivery system for intracellular delivery. The synthesized linoleic acid-grafted chitosan oligosaccharide (CSO-LA) with 10.3% graft ratio of LA could form micelles in aqueous with 86.69 μg/ml critical micellar concentration (CMC). The CSO-LA micelle had 46.2±3.6 nm number average diameter and 36.0±3.3 mV zeta potential. Taking doxorubicin base (DOX) as a model drug, the drug-loaded CSO-LA micelles (CSO-LA/DOX) was then prepared. The drug encapsulation efficiencies of CSO-LA/DOX were as high as 80%, and the drug loading capacity could be improved by increasing the charged DOX. Using MCF-7, Doxorubicin·HCl resistant MCF-7 (MCF-7/ADR), K562 and Doxorubicin·HCl resistant K562 (K562/ADR) cells as model drug sensitive and drug resistant tumor cells, the experiments demonstrated the CSO-LA had excellent cellular uptake ability by either drug sensitive tumor cells or drug resistance tumor cells. The CSO-LA micelles could deliver DOX into tumor cells, and the DOX in cells was increased with incubation time. As a result, the cytotoxicities of DOX encapsulated in CSO-LA micelles against drug resistance tumor cells were improved significantly, comparing to that of Doxorubicin·HCl solution.     

Redox-responsive nanoparticles from the single disulfide bond-bridged block copolymer as drug carriers for overcoming multidrug resistance in cancer cells

Multidrug resistance (MDR) is a major impediment to the success of cancer chemotherapy. The intracellular accumulation of drug and the intracellular release of drug molecules from the carrier could be the most important barriers for nanoscale carriers in overcoming MDR. We demonstrated that the redox-responsive micellar nanodrug carrier assembled from the single disulfide bond-bridged block polymer of poly(ε-caprolactone) and poly(ethyl ethylene phosphate) (PCL-SS-PEEP) achieved more drug accumulation and retention in MDR cancer cells. Such drug carrier rapidly released the incorporated doxorubicin (DOX) in response to the intracellular reductive environment. It therefore significantly enhanced the cytotoxicity of DOX to MDR cancer cells. It was demonstrated that nanoparticular drug carrier with either poly(ethylene glycol) or poly(ethyl ethylene phosphate) (PEEP) shell increased the influx but decreased the efflux of DOX by the multidrug resistant MCF-7/ADR breast cancer cells, in comparison with the direct incubation of MCF-7/ADR cells with DOX, which led to high cellular retention of DOX. Nevertheless, nanoparticles bearing PEEP shell exhibited higher affinity to the cancer cells. The shell detachment of the PCL-SS-PEEP nanoparticles caused by the reduction of intracellular glutathione significantly accelerated the drug release in MCF-7/ADR cells, demonstrated by the flow cytometric analyses, which was beneficial to the entry of DOX into the nuclei of MCF-7/ADR cells. It therefore enhanced the efficiency in overcoming MDR of cancer cells, which renders the redox-responsive nanoparticles promising in cancer therapy.     

Effect of hypothalamic hormones on the concentration of adenosine 3', 5'-monophosphate in incubated rat pineal glands.

Norepinephrine-stimulated accumulation of cyclic AMP in rat pineal was inhibited by TRH (0.1 ug/ml) but not by DDD-TRH, an inactive analog. LRH was less effective than TRH and SRIF had effects only at high concentration (30 ug/ml).     

TFPI1 Mediates Resistance to Doxorubicin in Breast Cancer Cells by Inducing a Hypoxic-Like Response

Thrombin and hypoxia are important players in breast cancer progression. Breast cancers often develop drug resistance, but mechanisms linking thrombin and hypoxia to drug resistance remain unresolved. Our studies using Doxorubicin (DOX) resistant MCF7 breast cancer cells reveals a mechanism linking DOX exposure with hypoxic induction of DOX resistance. Global expression changes between parental and DOX resistant MCF7 cells were examined. Westerns, Northerns and immunocytochemistry were used to validate drug resistance and differentially expressed genes. A cluster of genes involved in the anticoagulation pathway, with Tissue Factor Pathway Inhibitor 1 (TFPI1) the top hit, was identified. Plasmids overexpressing TFPI1 were utilized, and 1% O₂ was used to test the effects of hypoxia on drug resistance. Lastly, microarray datasets from patients with drug resistant breast tumors were interrogated for TFPI1 expression levels. TFPI1 protein levels were found elevated in 3 additional DOX resistant cells lines, from humans and rats, indicating evolutionarily conservation of the effect. Elevated TFPI1 in DOX resistant cells was active, as thrombin protein levels were coincidentally low. We observed elevated HIF1α protein in DOX resistant cells, and in cells with forced expression of TFPI1, suggesting TFPI1 induces HIF1α. TFPI1 also induced c-MYC, c-SRC, and HDAC2 protein, as well as DOX resistance in parental cells. Growth of cells in 1% O₂ induced elevated HIF1α, BCRP and MDR-1 protein, and these cells were resistant to DOX. Our in vitro results were consistent with in vivo patient datasets, as tumors harboring increased BCRP and MDR-1 expression also had increased TFPI1 expression. Our observations are clinically relevant indicating that DOX treatment induces an anticoagulation cascade, leading to inhibition of thrombin and the expression of HIF1α. This in turn activates a pathway leading to drug resistance.     

Low and high concentrations of the topo II inhibitor daunorubicin in NIH3T3 cells: reversible G2/M versus irreversible G1 and S arrest

Daunorubicin (DNR) blocks the cell cycle by interfering with synthesis and repair of DMA. In both drug-sensitive 3T3 cells and drug-resistant 3T3 cells (NIH-MDR-6185, created by transfection with a human MDR1 cDNA), low concentrations of DNR (up to 80 ng/ml in sensitive cells, 1600 ng/ml in resistant cells) initially slowed S-phase progression for 2 to 3 hours, but the treated cells then continued in progression at a steady rate, close to that of untreated cells, and accumulated in G(2)/M. The 2 to 3 h lag period represents the time taken for fully establishing the G(2)/M block. The time required to bring about cessation of proliferation is the sum of this lag period and the time taken to travel through the cell cycle. This low concentration effect is cytostatic, and fully reversible on washing out the daunorubicin. At higher drug concentrations (above 160 ng/ml in sensitive cells, 3200 ng/ml in resistant cells) the cells became blocked in both G] and S, and did not reach G(2)/M. The high concentration effect was cytotoxic and irreversible, and was followed by cell death. Only cells that were in S phase were subject to this block in S, since cells that had accumulated in G(2)/M by using a low concentration (60 ng/ml DNR for 20 h) were not blocked in S, and did not die, when subsequently treated with high drug concentrations (320 ng/ml, 30 h). The low concentration effect occurred at the same maximal rate (4 %/h) in sensitive or resistant cells, but the external drug concentration required to produce half the maximal rate was, appropriately, twenty-fold higher in the resistant cells (20 ng/ml and 400 ng/ml, respectively).     

Expression of herpes simplex virus type-common surface antigens in clonal cells of an HSV type 2-transformed line: effect of adriamycin

The expression of herpes simplex virus (HSV) type-common surface antigens (CSA) in a representative cell clone (155-4-03) of hamster cell line 155-4 transformed by HSV type 2 was enhanced by treatment with inhibitors of RNA synthesis [adriamycin (ADM) and daunomycin] but not with inhibitors of DNA synthesis (2-iododeoxyuridine, bleomycin, mitomycin C and cytosine arabinoside), although all these drugs decreased the number of viable cells to a similar extent. ADM-enhanced CSA expression in the clone was inhibited by puromycin and 2-deoxy-d-glucose, suggesting that the enhanced expression required both protein synthesis and glycosylation. This enhanced expression was sensitive to protease inhibitors (antipain and p-nitrophenyl-p'-guanidinobenzoate) and procaine, which is known to inhibit trypsin action and the organization of cell membrane-associated cytoskeletal elements (microfilaments and microtubules). Furthermore, low concentrations of ADM (0.1 microgram/ml) and actinomycin D (0.5 microgram/ml) enhanced CSA expression additively, but the most effective concentrations of ADM (0.25 microgram/ml) and actinomycin D (2 microgram/ml) did not. These findings indicated that the two drugs enhance CSA expression in the clone by a common mechanism.     

Low and High Concentrations of the Topo II Inhibitor Daunorubicin in NIH3T3 Cells: Reversible G2/M Versus Irreversible G1 and S Arrest

Daunorubicin (DNR) blocks the cell cycle by interfering with synthesis and repair of DNA. In both drug-sensitive 3T3 cells, and drug-resistant 3T3 cells, NIH-MDR-6815, (created by transfection with a human MDR1 cDNA), low concentrations of DNR (up to 80 ng/ml in sensitive cells, 1600 ng/ml in resistant cells), cells initially slowed S-phase progression for 2 to 3 hours, but the treated cells then continued in progression at a steady rate, close to that of untreated cells and accumulated in G2/M. The 2 to 3 h lag period represents the time taken for fully establishing the G2/M block. The time required to bring about cessation of proliferation is the sum of this lag period and the time taken to travel through the cell cycle. This low concentration effect is cytostatic, and fully reversible on washing out the daunorubicin. At higher drug concentrations (above 160 ng/ml in sensitive cells, 3200 ng/ml in resistant cells) the cells became blocked in both G1 and S, and did not reach G2/M. The high concentration effect was cytotoxic and irreversible, and was followed by cell death. Only cells that were in S phase were subject to this block in S, since cells that had accumulated in G2/M by using a low concentration (60 ng/ml DNR for 20 h) were not blocked in S, and did not die, when subsequently treated with high drug concentrations (320 ng/ml, 30 h). The low concentration effect occurred at the same maximal rate (4 %/h) in sensitive or resistant cells, but the external drug concentration required to produce half the maximal rate was, appropriately, twenty-fold higher in the resistant cells (20 ng/ml and 400 ng/ml, respectively).     

Effects of cis-unsaturated fatty acids on doxorubicin sensitivity in P388/DOX resistant and P388 parental cell lines

It has been reported that several cis-unsaturated fatty acids (c-UFAs) could increase doxorubicin (DOX) accumulation in cancer cells and hence elevate its cytotoxicity. However, some researchers showed that c-UFA pretreatment did not affect its cytotoxicity in special cell lines. It is possible that the different results occurred due to different cellular characteristics. We hypothesized that c-UFA treatment might modulate the activities of some antioxidant enzymes to affect the resistance of cells to DOX. In the present study, we examined how c-UFA pretreatment affected DOX cytotoxicity on mouse leukemia cell line, P388, and its resistant subline, P388/DOX, which we found to have significantly higher glutathione peroxidase (GPx) activity as well as P-glycoprotein (p-gp) overexpression. We chose two c-UFAs, gamma-linolenic acid (GLA) (18:3n-6) and docosahexaenoic acid (DHA) (22:6n-3). Cytotoxicity was measured by MTT (3-(4.5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) and trypan blue exclusion assays. DOX accumulation and p-gp expression were measured by flow cytometry. The activities of catalase (CAT), superoxide dismutase (SOD), glutathione S-transferase (GST), and GPx were determined for both cell lines with and without treatment with GLA or DHA. Significant DOX accumulation occurred in both cell lines with GLA or DHA pretreatment, but without any change in p-gp expression in either cell line. Sensitivity to DOX cytotoxicity was improved by GLA or DHA pretreatment in P388/DOX in which only SOD activity was significantly increased, but not in the parental cell line P388 in which both SOD and CAT were significantly increased by the pretreatment. However, combined pretreatment of GLA or DHA with antioxidants, pyrrolidinedithiocarbamate (PDTC) or Vitamin C, could sensitize not only P388/DOX but also P388 cells to DOX. We conclude that the effects of c-UFA pretreatment on the sensitivity of cancer cells to DOX not only depend on the change in drug accumulation but also the change in the levels of antioxidant enzyme activities, and suggest that combined administration of c-UFAs, antioxidants, and DOX may be more effective in treating leukemia.     

Comparative accumulation of the Hoechst 33258 fluorescent probe in leukemia P388 cells sensitive and resistant to doxorubicin

The authors studied accumulation of the fluorescent probe Hoechst 33258 in leukemia P 388 sensitive (P 388/0) and resistant to doxorubicin (P 388/DOX) cells. It was shown that intensity of fluorescence of the dye increased after binding with nuclear DNA during 25 min for both lines of the cells. Intensity of fluorescence was 40% greater in sensitive than resistant cells. If Triton X-100 was added no difference between two lines of the cell was observed. When doxorubicin was added to the cells with dye, the intensity of fluorescence decreased. It was suggested to use Hoechst 33258 for assessment extent doxorubicin accumulation in nuclei of the cells.